Savara Inc. has released a corporate presentation detailing its ongoing work in developing new therapies for rare respiratory diseases. The presentation highlights MOLBREEVI (the conditionally accepted trade name for molgramostim inhalation solution), which recently demonstrated clinically meaningful positive Phase 3 results for the treatment of autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Data suggest that MOLBREEVI may address the underlying pathophysiology of autoimmune PAP, with a favorable benefit/risk profile and good tolerability observed. The company plans to resubmit its Biologics License Application (BLA) by December 2025. The executive leadership team includes Chair & CEO Matthew Pauls, Chief Business Officer Anne Erickson, Chief Financial & Administrative Officer Dave Lowrance, Chief Operating Officer Rob Lutz, Chief Legal Officer Kate McCabe, Chief Commercial Officer Braden Parker, Chief Medical Officer Ray Pratt, EVP of Global Technical Operations Sid Advant, EVP of Global Regulatory Affairs Charles LaPree, EVP of Global Medical Affairs Brian Robinson, and EVP of Clinical Operations/Development Yasmine Wasfi. You can access the full presentation through the link below.